Trial status: Completed

Trial name: Atomoxetine and Huntington's Disease

FDA phase: Phase II

Sponsor: Eli Lilly and Company

Trial results: The study showed that there was no positive effect from atomoxetine on daily activities such as attention and focus, thinking ability, and muscle movements.

Location: University of Iowa